Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Issue 3 (4th March 2017)

• Record Type: Journal Article
• Authors: Pozzi, Samantha; Gentile, Massimo; Sacchi, Stefano; Marcheselli, Raffaella; Corso, Alessandro; Cocito, Federica; Musto, Pellegrino; Guarini, Attilio; Minoia, Carla; Vincelli, Iolanda; Ria, Roberto; Rivolti, Elena; Mele, Giuseppe; Bari, Alessia; Mazzone, Carla; Badiali, Stefania; Marcheselli, Luigi; Palumbo, Antonio; Morabito, Fortunato
• Is Part Of: Leukemia & lymphoma. Volume 58:Issue 3(2017)
• Page Start: 552
• Page End: 559
• Publication Date: 2017-03-04
• Subjects: Multiple myeloma -- lenalidomide -- bendamustine -- clinical trial; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2016.1205741
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing escalating doses of bendamustine and lenalidomide and fixed low doses of dexamethasone (BdL). Fifteen patients were enrolled in phase I study. Maximum tolerated dose was established at dose "level 0": bendamustine 40 mg/m 2 days 1, 2; lenalidomide 10 mg days 1–21; d 40 mg days 1, 8, 15, 22 every 28-day cycle, for six cycles. We enrolled 23 patients in the phase II study. BdL combination showed mainly hematological toxicities, fever and infections. Overall response rate was 47%. After median follow up of 22 months, median PFS was 10 months. Two-years OS rate was 65%. BdL combination confirmed to be a promising treatment for patients with relapsed/refractory MM.